OTLK vs. CRIS, PASG, ALVR, PLX, ATHA, GRTS, DBVT, JATT, ELUT, and DTIL
Should you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Curis (CRIS), Passage Bio (PASG), AlloVir (ALVR), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Gritstone bio (GRTS), DBV Technologies (DBVT), JATT Acquisition (JATT), Elutia (ELUT), and Precision BioSciences (DTIL). These companies are all part of the "biological products, except diagnostic" industry.
Outlook Therapeutics (NASDAQ:OTLK) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
Outlook Therapeutics currently has a consensus target price of $46.43, indicating a potential upside of 524.83%. Curis has a consensus target price of $37.33, indicating a potential upside of 187.18%. Given Outlook Therapeutics' higher possible upside, research analysts plainly believe Outlook Therapeutics is more favorable than Curis.
Curis has higher revenue and earnings than Outlook Therapeutics. Outlook Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Outlook Therapeutics has a net margin of 0.00% compared to Curis' net margin of -486.45%. Curis' return on equity of -224.75% beat Outlook Therapeutics' return on equity.
Outlook Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500.
In the previous week, Curis had 13 more articles in the media than Outlook Therapeutics. MarketBeat recorded 20 mentions for Curis and 7 mentions for Outlook Therapeutics. Outlook Therapeutics' average media sentiment score of 0.60 beat Curis' score of 0.53 indicating that Outlook Therapeutics is being referred to more favorably in the media.
11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 5.3% of Outlook Therapeutics shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Curis received 534 more outperform votes than Outlook Therapeutics when rated by MarketBeat users. However, 70.32% of users gave Outlook Therapeutics an outperform vote while only 67.65% of users gave Curis an outperform vote.
Summary
Curis beats Outlook Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Outlook Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outlook Therapeutics Competitors List
Related Companies and Tools
